NRx shares jump 39% on new clinical data testing its experimental COVID-19 drug in the critically ill
NRx shares jump 39% on new clinical data testing its experimental COVID-19 drug in the critically ill
Shares of NRx Pharmaceuticals Inc. (NRXP) soared 39.9% in premarket trading on Thursday after the company said new peer-reviewed data published in the Journal of Infectious Diseases and Treatment showed that its experimental COVID-19 therapy improved survival in critically ill patients. The data came from an open-label trial assessing respiratory failure in 21 patients who were too sick to participate in the company's Phase 2b/3 trial evaluating the drug, aviptadil, in COVID-19 patients with respiratory failure. NRx said there were no adverse events, though low blood pressure was reported and managed in two patients. NRx's stock is down 61.3% so far this year, while the broader S&P 500 is up 16.1%.
週四盤前交易中，NRX製藥公司(NRX PharmPharmticals Inc.)股價飆升39.9%，此前該公司表示，發表在《傳染病與治療雜誌》上的最新同行評議數據顯示，其實驗性新冠肺炎療法提高了危重患者的存活率。這些數據來自一項開放試驗，該試驗評估了21名患者的呼吸衰竭，這些患者病情嚴重，無法參加該公司在新冠肺炎呼吸衰竭患者中評估藥物Aviptadil的2b/3期試驗。NRX表示，儘管有兩名患者報告並控制了低血壓，但沒有不良事件發生。NRX股價今年迄今下跌61.3%，而大盤標普500指數上漲16.1%。
-Jaimy Lee
--傑米·李(Jaimy Lee)